JP Patent

JP2003206227A — 薬物の経鼻投与用組成物

Assigned to Translational Research Ltd · Expires 2003-07-22 · 23y expired

What this patent protects

(57)【要約】【課題】薬物の生体内吸収効率の改良された経鼻投与用組成物の提供。【解決手段】特定の粒径を有する結晶セルロースおよび／または部分アルファー化デンプン粒子を薬物の担体とする経鼻投与用組成物。

USPTO Abstract

(57)【要約】【課題】薬物の生体内吸収効率の改良された経鼻投与用組成物の提供。【解決手段】特定の粒径を有する結晶セルロースおよび／または部分アルファー化デンプン粒子を薬物の担体とする経鼻投与用組成物。

Drugs covered by this patent

dihydroergotamine-mesylate (DIHYDROERGOTAMINE MESYLATE)

Patent Metadata

Patent number: JP2003206227A
Jurisdiction: JP
Classification: —
Expires: 2003-07-22
Drug substance claim: No
Drug product claim: No
Assignee: Translational Research Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.